In other recent news, Akero Therapeutics has been the focus of several analyst upgrades following the release of positive ...

A drug developed by US biotech Akero Therapeutics has hit the mark in a phase 2b trial in non-alcoholic steatohepatitis (NASH) – catapulting it to the forefront of efforts to find effective ...

If you own Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO), please contact Fletcher Moore by email at [email protected] or (212) 709-8245. You may be able to seek monetary damages ...

Akero Therapeutics' EFX showed remarkable efficacy in reversing cirrhosis in the long-term SYMMETRY trial, a significant milestone in MASH treatment. EFX demonstrated consistent efficacy across ...

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have been assigned an average recommendation of “Buy” from the nine ratings firms that are covering the company ...

NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Akero Therapeutics Inc (Symbol: AKRO) entered into oversold territory, hitting an RSI ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...